These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 27951441)

  • 1. Resistance to PD1/PDL1 checkpoint inhibition.
    O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
    Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
    O'Donnell JS; Smyth MJ; Teng MW
    Genome Med; 2016 Oct; 8(1):111. PubMed ID: 27782862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.
    Nowicki TS; Anderson JL; Federman N
    Pediatr Res; 2016 Mar; 79(3):371-7. PubMed ID: 26595537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
    Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
    Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.